The themes Sanara Medtech is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
Built from Sanara Medtech Inc.’s own filings with the U.S. Securities and Exchange Commission (SEC). Figures are as reported, with per-share history restated onto today’s share basis. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.
SMTI · Nasdaq · Healthcare · Medical Instruments and Supplies
$32.35-0.6%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed November 12, 2026
Company outlook: revenue of $110M to $115M for Fiscal year 2026 — up 9.1% on a year earlier
Just reported
From Sanara Medtech's results release of November 12, 2026; its quarterly report has since been filed.
Actual
$28.4M
+8.0% y/y
+1.0% q/q
Guided
—
No guide given
Actual
$736K
-75% y/y
-59% q/q
Guided
—
No guide given
Q3 2026
Full year 2026
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Grade B-
The band under the price shows the grade on each date, built only from filings that were public by then.
Showing 2 of 40 quarters of Sanara Medtech Inc.’s grade history. The other 38 go back to November 2016.